Secreted $\beta_3$-Integrin Enhances Natural Killer Cell Activity against Acute Myeloid Leukemia Cells

Younis Skaik, Stefanie Vahlsing, Lilia Goudeva, Britta Eiz-Vesper, Anja Battermann, Rainer Blasczyk, Constança Figueiredo*

Institute for Transfusion Medicine, Hannover Medical School, Hannover, Germany

Abstract

Integrins are a large family of heterodimeric proteins that are involved in cell adhesion, migration, and proliferation. Integrin diversity and function is regulated by alternative splicing. Membrane-bound and truncated $\beta_3$-integrins were shown to be key players in cancer metastasis. However, the immunomodulatory functions of the soluble (s) $\beta_3$-integrin have not been investigated yet. In this study, we described a novel form of s$\beta_3$-integrin in acute myeloid leukaemia (AML) patients. Furthermore, we assessed the role of the s$\beta_3$-integrin in the modulation of natural killer (NK)-cell activity. Levels of s$\beta_3$-integrin were analysed in plasma samples of 23 AML patients and 26 healthy donors by ELISA. The capacity of s$\beta_3$-integrin to regulate NK cell activity was investigated using proliferation, cytokine secretion, and cytotoxicity assays. Circulating s$\beta_3$-integrin was detected in the plasma of 8 AML patients. NK cells showed significantly higher proliferation rates after stimulation with s$\beta_3$-integrin and IL-2, IL-15 (73%). Significant increases in the NK cells’ secreted levels of TNF-$\alpha$, IFN-$\gamma$ were measured in presence of s$\beta_3$-integrin. In addition, s$\beta_3$-integrin caused the upregulation of Granzyme B transcripts levels as well as FasL expression levels in NK cells. Most importantly, significantly higher K562 or AML blast target cell lysis rates were observed when NK cells were exposed to s$\beta_3$-integrin. This study reports the identification of a novel s$\beta_3$-integrin in AML patients and provides novel insights into its role in the immunomodulation of NK cell activity.

Introduction

Integrins exist as obligate heterodimeric receptors, which are constituted of $\alpha$ and $\beta$ transmembrane subunits. Each subunit consists of a large extracellular domain, a single-transmembrane domain, and a short cytoplasmic tail [1]. Integrins serve mainly as sensors for extracellular matrix ligands and cell surface ligands [2,3]. Alternative splicing is an important mechanism to increase the functional diversity of integrins [4]. $\alpha_\text{V}\beta_3$ and $\alpha_\text{IIb}\beta_3$ integrins are constitutively expressed by angiogenic endothelial cells and platelets, respectively [5]. Although previous studies have shown that both membrane-bound and soluble (s) forms of $\beta_3$-integrin are strongly associated with tumor cancer metastasis [6,7], the immunomodulatory functions of the s$\beta_3$-integrins remain unclear.

Acute myeloid leukemia (AML) is a frequent malignant hematological disease characterized by the initial accumulation of immature leukemia cells in the bone marrow and their subsequent migration into the blood circulation [8]. Natural Killer (NK) cells are key players in the immune surveillance of AML [9], and able to eradicate leukemic cells in an autologous or allogeneic setting [10,11]. NK cell activity has been positively correlated with relapse-free survival after haematopoietic stem cell transplantation [12,13]. NK cells use different strategies to eliminate their leukemic targets. NK cell-mediated clearance of leukemic cells may be induced by the secretion of perforins, granzymes and cytokines such as IFN-$\gamma$ or TNF-$\alpha$. Furthermore, NK cells are capable to upregulate the expression of Fas ligand (FasL, CD95L) to engage cell death receptors such as FAS/CD95 present on their target cells and thereby causing their apoptosis [14,15,16]. Previously, secretion of s$\beta_3$-integrin was demonstrated on human erythroleukemia (HEL) cells [17]; however its role in the modulation of NK cell activity against leukemic blasts remained unclear. In this study we describe, for the first time to our knowledge, a novel s$\beta_3$-integrin variant in the plasma of AML patients. In addition, we have investigated the role of this alternative spliced s$\beta_3$-integrin on the immunomodulation of NK cell activity. Our results show that s$\beta_3$-integrin specifically enhances the cytotoxic activity of NK cells against leukemic target cells.

Materials and Methods

Patient and Control Samples

Plasma of 23 patients suffering of AML or secondary AML (sAML) following myelodysplastic syndromes (MDS) or without MDS antecedent (Table S1) was collected before and after chemotherapy. Informed written consent was obtained from all patients and approved by the local ethics committee of the Hannover Medical School. In addition, this study was also approved by the same committee and followed the principles expressed in the declaration of Helsinki. Twenty-six plasmas from...
healthy donors were used as controls. Plasmas from other myeloproliferative diseases (non-AML); acute lymphoblastic leukemia (ALL) (n = 1), chronic lymphoid leukemia (CLL) (n = 1), and non-Hodgkin lymphoma (NHL) (n = 1) were also collected prior and after chemotherapy.

**Detection of \( \beta_3 \)-integrin by ELISA**

Maxisorp ELISA plates (Nunc, Wiesbaden, Germany) were coated with one-hundred \( \mu L \) undiluted or diluted plasma and incubated overnight at 4°C. Then, plates were washed with phosphate-buffered saline (PBS) and blocked with 2% BSA/PBST for 1 hour at room temperature (RT). After washing with PBS, 100 \( \mu L \) of the primary monoclonal antibody (MoAb) SZ-21 (Beckman Coulter, Marseille, France), CRC54 (antibodies-online GmbH, Aachen, Germany), Y2/51 (antibodies-online GmbH, Aachen, Germany), ZS-22 (Beckman Coulter, Marseille, France), P2 (Beckman Coulter, Marseille, France), or AP2 (GTI Diagnostic, Wisconsin, USA) were added to the plates previously pre-coated with plasmas. The specificity of each MoAb has been previously described [18]. After washing, 100 \( \mu L \) of the HRP-conjugate anti-mouse-IgG (Rockland Inc., Gilbertsville, PA, USA) were added to each well and incubated for 2 hours at RT. After addition of the 3,3’, 5,5’-Tetramethyl-benzidin substrate (Dako, Hamburg, Germany), optical densities (OD) were measured at 450 nm using the TECAN Synergy (Tecan Deutschland GmbH, Crailsheim, Germany). The thermal cycling conditions used were as follow: 94°C for 5 min, 30 cycles of 94°C for 20 sec, 60°C for 1 min, 72°C 2 min followed by a final extension of 72°C for 5 min. Fragments amplified during PCR were cloned into the plasmid pcDNA3.1 following the manufacturer's instructions (Life technologies, Karlsruhe, Germany).

**Expression of Recombinant Soluble \( \beta_3 \)-integrin in HEK293**

Soluble \( \beta_3 \)-integrin was produced recombinantly in HEK293 as previously described [19]. The recombinant soluble \( \beta_3 \)-integrin sequence was designed based on the RNA sequence detected in the AML patient’s serum. Briefly, a lentiviral vector encoding the sequence for soluble \( \beta_3 \)-integrin as previously described [19] was used to amplify \( \beta_3 \)-integrin from each patient and control cDNA sample. \( \beta_3 \)-integrin was amplified in PCR reactions using specific primers and the Bio-X-ACT short mix (Bioline, Luckenwalde, Germany). The thermal cycling conditions used were as follow: 94°C for 5 min, 30 cycles of 94°C for 20 sec, 60°C for 1 min, 72°C 2 min followed by a final extension of 72°C for 5 min. Fragments amplified during PCR were cloned into the plasmid pcDNA3.1 following the manufacturer’s instructions (Life technologies, Karlsruhe, Germany).

**Purification of soluble \( \beta_3 \)-integrin Using Immobilized Metal Affinity Chromatography**

Soluble \( \beta_3 \)-integrin V5/His-tagged was purified from the cell-culture supernatant (pH 8.0) using HisTrap HP columns (Sigma-Aldrich Chemie, Steinheim, Germany), and the BioLogic DuoFlow System (Bio-Rad, Hercules, USA). Concentrations of soluble \( \beta_3 \)-integrin were determined using the bicinchoninic acid protein assay kit (Perbio Science, Bonn, Germany) and confirmed by ELISA using anti-V5 and HRP-anti-His as the capture and detection antibodies, respectively. Known amounts of V5-His-
tagged β3-integrin protein were used as the reference standard. Produced sβ3-integrin was controlled for quality controlled by sodium dodecylsulfate (SDS) and immunoblot as previously described [19].

**Natural Killer Cell Isolation**

Isolation of NK cells from PBMCs of healthy donors was performed by magnetic cell separation using the human NK-cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), according to the manufacturer’s instructions. NK cells were identified using phycoerythrin (PE)-conjugated anti-NKp46 (Beckman Coulter Marseille, France) antibodies, and analysed using a FACSCanto flow cytometer (BD Biosciences, Immunocytometry Systems, San Jose, Calif, USA). Purities of isolated NK cells were higher than 95% in all experiments.

**Culture and Stimulation of NK Cells**

Freshly isolated NK cells were cultured in RPMI medium (BioWhittaker/Cambrex, Hess. Oldendorf, Germany) supplemented with 10% human AB serum (C.C. Pro, Neustadt, Germany). For stimulation, NK cells were cultured in presence of the stimulatory cytokine IL-2 (100 U/ml) alone or in combination with IL-15 (50 ng/ml), only recombinant sβ3-integrin (5 μg/ml), or a cocktail including the cytokines and sβ3-integrin at the indicated concentrations. Both recombinant cytokines were purchased from PeproTech Inc. (Rocky Hill, USA). Non-stimulated NK cells were used as negative control (NS). A control protein was used to assess the specificity of the sβ3-integrin effect on NK cells. This control protein is a truncated form of a killer-immunoglobulin-like receptor (trKIR) protein produced and isolated similarly to sβ3-integrin and denatured prior its use as negative control (NC) by incubation at 56°C for 1 hour.

---

**Figure 2. Characterization of sβ3-integrin detected in AML patient.** (A) Total RNA was prepared from peripheral blood mononuclear cells (PBMCs) of leukemic patients and was reverse transcribed in cDNA. The sβ3-integrin sequence was amplified by PCR using specific primers. sβ3-integrin sequences (1201 bp) were detectable in AML patients. Negative controls were also used as described in Materials and Methods. (B) Primer sequences used in the amplification and sequencing of truncated β3-integrin. Primers used in the sequencing reactions are highlighted. doi:10.1371/journal.pone.0098936.g002
Immunofluorescence

NK cells (1×10^5 cells) were cultured on gelatinised 8-well Lab-Tek slides (Nunc, Rochester, USA), fixed with Cytofix (BD Bioscience). Five μg of His-tagged sβ3-integrin protein were added to the culture for 8 h. After washing, protein binding was detected using an anti-His antibody. NK cells cultured in the absence of sβ3-integrin were used as control. The samples were mounted in ProLong Antifade kit (Molecular Probes) and analysed using the 40x magnification lens of an Olympus IX81 microscope system and the Cell'M software (Olympus, Hamburg, Germany).

Proliferation Assay

Freshly isolated NK cells were labelled with carboxyfluorescein succinimidyl ester (CFSE) purchased from Invitrogen (Vybrant CFSE Cell Tracer Kit, Carlsbad, USA) at a final concentration of 4 μM. CFSE-labelled NK cells were incubated under the described conditions. After 7 days, NK-cell proliferation was assessed based on CFSE dilution using flow cytometry.

Phenotype and Cytokine Secretion Assay

For phenotype and cytokine secretion analysis, freshly isolated NK cells were incubated under the described conditions for 48 hours. Expression levels of CD95L were determined by flowcytometric analyses upon cell staining with phycoerythrin-conjugated antibodies purchased at Beckman Coulter. Supernatants of NK-cell cultures were then collected and analyzed for cytokine secretion using Luminex technology (MILLIPLEX Human Cytokine/Chemokine 14-plex panel, Millipore, Billerica, MA, USA; Luminex 200TM instrument, Invitrogen).

Table 1. Natural killer (NK) cell cytokine secretion profile.

| Analyte pg/ml | NC          | IL-2        | GPIllα       | GPIllα + IL-2 | KIR           | KIR + IL-2         |
|--------------|-------------|-------------|--------------|---------------|----------------|--------------------|
| TNF-α        | 4.1±0.4     | 21.6±2.5    | 4.1±0.2      | 36.2±2.9 (*)  | 3.6±0.1        | 19.4±0.2           |
| IFN-γ        | 3.2±0.0     | 72.2±1.5    | 3.2±0.0      | 91.5±10.3 (*) | 3.2±0.0        | 61.1±9.4           |

Cytokine secretion was analysed in four independent experiments. Levels of significance were expressed as p-values (*p<0.05).

doi:10.1371/journal.pone.0098936.t001
Real-Time PCR

Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany) and reverse transcribed into cDNA using the high-capacity cDNA reverse transcriptase kit (Applied Biosystems, Carlsbad, USA). Five ng of RNA was used for each experiment. Quantitative Real Time PCR was performed using the Real time-PCR Master Mix and the OneStep Plus RT system (Applied Biosystem). Primers were designed to amplify transcripts of Granzyme B as previously described [20]. Expression data was normalized using the reference gene β-actin.

NK Cell Cytotoxic Assays

Freshly isolated NK cells were cultured in the conditions described above. After 48 h, NK cells were exposed to CFSE-labelled K562 cells at an effector:target (E:T) ratio of 5:1 (effector:target) ratio. Target cell lysis was detected by flow cytometric analysis upon 7-aminoactinomycin D (7-AAD) staining. The figure shows the mean and standard deviation (mean±SD) of K562 cell lysis detected in four separated experiments. Levels of significance were expressed as p-values (*p<0.05, **p<0.01, ***p<0.001).

Figure 4. Soluble β3-integrin increases the cytotoxic potential of NK cells. Freshly isolated NK cells were cultured in presence or absence of 5μg/ml sβ3-integrin alone or in combination with IL-2 for 48 h. Non-stimulated NK cells or exposed to a control protein were used as controls. Granzyme B transcript levels were analysed by real time PCR. Housekeeping gene β-actin was used for normalization of cDNA levels. Figure depicts the mean and standard deviations (mean±SD) of values obtained in four separate experiments. Levels of significance were expressed as p-values (*p<0.05, **p<0.01, ***p<0.001).

Figure 5. Expression of FasL is significantly upregulated upon sβ3-integrin exposure. Expression of FasL (CD95L) was detected on NK cells previously stimulated with 5 μg/ml sβ3-integrin alone or in combination with IL-2 for 48 h. Non-stimulated NK cells were also used as control. FasL expression levels were assessed by flow cytometric analyses. (A) Representative dotplots of FasL expression levels upon NK cell culture in the conditions described in Material and Methods. (B) The figure represents the mean and standard deviation (mean±SD) of FasL expression levels detected in four independent experiments. Levels of significance were expressed as p-values (*p<0.05, **p<0.01, ***p<0.001).

Figure 6. Soluble β3-integrin increases NK cell cytotoxic activity against K562 leukemia cells. Cytotoxic assays using NK cells previously cultured in the presence or absence of sβ3-integrin alone or in combination with IL-2 were exposed to primary K562 cells for 6 h at 5:1 (effector:target) ratio. Target cell lysis was detected by flow cytometric analysis upon 7-aminoactinomycin D (7-AAD) staining. (A) The figure shows the mean and standard deviation (mean±SD) of K562 cell lysis detected in four separated experiments. Levels of significance were expressed as p-values (*p<0.05, **p<0.01, ***p<0.001).

Figure 6. Soluble β3-integrin increases NK cell cytotoxic activity against K562 leukemia cells. Cytotoxic assays using NK cells previously cultured in the presence or absence of sβ3-integrin alone or in combination with IL-2 were exposed to primary K562 cells for 6 h at 5:1 (effector:target) ratio. Target cell lysis was detected by flow cytometric analysis upon 7-aminoactinomycin D (7-AAD) staining. (A) The figure shows the mean and standard deviation (mean±SD) of K562 cell lysis detected in four separated experiments. Levels of significance were expressed as p-values (*p<0.05, **p<0.01, ***p<0.001).
were performed to determine the effect and specificity of sβ3-integrin in the lysis of primary leukemia cells. For this purpose, AML blasts were enriched to reach a cell purity by up to 85% by cell sorting (FACSaria, BD Biosciences, San Jose, CA) and used as target cells. NK cells were treated with Fc receptor blocking reagent (Miltenyi Biotec) and exposed to sβ3-integrin in presence or absence of IL-2 and an anti-β3-integrin antibody (10 µg/ml; BD Biosciences). NK cell cytotoxic assays were performed and analysed as described above.

Statistical Analysis
Statistical differences among means of two groups were calculated using the t-test. Differences between more than 2 groups were calculated using ANOVA. Statistical analyses were calculated using the GraphPad Prism 5 software (GraphPad Software, San Diego, CA). P values of less than 0.05 were considered significant.

Results
Detection of Soluble β3-integrin in Sera of AML Patients
Previously, we have established an ELISA for the detection of sβ3-integrin [19]. In this study, we have detected sβ3-integrin in 35% of AML patients (n = 8) prior chemotherapy. Significantly increased levels of sβ3_integrin were observed in AML patients in comparison to those detected after conditioning or in healthy individuals (p = 0.007, p = 0.0019, respectively). To confirm our findings, we used three different β3-integrin-specific murine MoAbs (SZ-21, CRC54, and Y2/51) and three control MoAbs (SZ-22, P2 and AP2) which recognize GPIIb alone, and the heterodimer GPIIb-IIIa, respectively. As expected, control MoAbs did not react with the sβ3-integrin (OD450 nm range: 0.051–0.064) (Figure 1). Levels of sβ3-integrin were increased in patients showing different AML subtypes (M2 n = 2, M4 n = 1, M5 n = 2 and sAML n = 3) prior chemotherapy. No significant differences in sβ3-integrin levels were observed in non-AML patients prior or after chemotherapy (p = 0.0698) (Figure 1). These results suggest that the increase in sβ3-integrin levels is specific for AML patients.

Identification of Alternatively Spliced Soluble Truncated β3-integrin
Previous studies showed that truncated alternative spliced β3-integrin can be secreted by tumour cells and deposited on the extracellular matrix [6]. To determine whether the sβ3-integrin detected in AML patient samples was generated by alternative splicing, trβ3-integrin coding sequence was amplified from cDNA patients’ samples using primers flanking the ATG initiation codon and the translation premature termination codon (intron 8) (Figure 2A-B). A sequence of 1201 bp was obtained. This novel trβ3-integrin sequence shows a unique intron 8 which differs from the wild type (wt) β3-integrin (Figure S1 A–C). This new intron 8 contains a premature stop codon which causes the lack of the transmembrane and cytoplasmic domain in the translated mature protein. These data indicate that the trβ3-integrin found in the plasma of AML patients is produced by the alternative splicing and not a pseudogene or a degraded protein fragment.

Soluble β3-integrin Increases NK Cell Proliferation
NK cells are essential effector cells contributing for the reduction of the tumour burden [21,22]. Therefore, it is important to evaluate the effect of proteins specifically detected in leukaemia patients in NK cell function. In this study, all functional assays were performed using recombinant sβ3-integrin which was produced as previously described [19]. Fluorescence microscopy analyses showed that sβ3-integrin is capable of binding NK cells (Figure 3A). We have investigated whether sβ3-integrin is capable of modulating NK cell proliferation. Interestingly, we have observed a significant increase in NK cell proliferation rates when these were cultured with IL-2, IL-15 and sβ3-integrin (73%±5%, p<0.05) in comparison to the cells cultured only with the cytokine cocktail (45.6%±9.2%). Also, sβ3-integrin-stimulated NK cell proliferation rates were superior than those observed after NK cell exposure to the cytokine cocktail and the control protein (49.8%±10.8%, ns). In the absence of cytokine cocktail, sβ3-integrin did not show an effect on the NK cell proliferation (19.9%±0.2%) compared to non-stimulated NK cells (22.2%±0.3%) (Figure 3B). These data suggest that sβ3-integrin may act synergistically with stimulating cytokines to enhance NK cell proliferation.

Soluble β3-integrin Induces the Secretion of Pro-inflammatory Cytokines
Cytokines are crucial mediators and effector molecules during the immune response [23]. We have determined the effect of sβ3-integrin in the secretion of cytokines. Significant increases in the secretion levels of TNF-α (36.2±2.9 pg/mL, p<0.05) and IFN-γ (91.5±10.3 pg/mL, p<0.05) were detected upon NK cell culture in presence of sβ3-integrin in combination with IL-2 in comparison to the cytokine levels detected when the NK cells were only cultured in presence of IL-2 (TNF-α: 21.6±2.5; IFN-γ: 72.2±1.5 pg/mL). Stimulation of NK cells with sβ3-integrin in the absence of IL-2 did not affect the secretion levels of TNF-α or IFN-γ (Table 1). These data suggest that sβ3-integrin supports the secretion of pro-inflammatory cytokines which might have a direct cytotoxic effect or contribute to amplify the immune response.

Soluble β3-integrin Induces an Increase in Granzyme B Transcript Levels
Granzyme B is an important mechanism used by NK cells to induce the death of the target cells and it plays a crucial role in the control of tumor growth in vivo [24]. We have investigated whether sβ3-integrin may affect the cytotoxic potential of NK cells.
Interestingly, significant higher Granzyme B transcripts levels were detected in \( \beta_3 \)-integrin-stimulated NK cells in presence of IL-2 (RQ: 2.6 ± 0.2, p < 0.05) in comparison to NK cells cultured with IL-2 alone (RQ: 1.9 ± 0.3) or with the control protein in combination with IL-2 (RQ: 1.8 ± 0.1). Also, NK cell stimulation with \( \beta_3 \)-integrin in the absence of IL-2 caused a significant increase of granzyme B transcript levels (RQ: 1.3 ± 0.1) in comparison to non-stimulated NK cells (RQ: 1 ± 0.1) or stimulated with the control protein (RQ: 1.8 ± 0.1) (Figure 5A). Similar to the effect on granzyme B, also NK cell stimulation with \( \beta_3 \)-integrin alone induced a significant upregulation of FasL expression (3.3% ± 0.3%, p < 0.01) in comparison to non-stimulated NK cells (0.3% ± 0.2%) or stimulated with a control protein (0.2% ± 0.1%) (Figure 5B). Soluble \( \beta_3 \)-integrin showed to induce a strong upregulation of FasL on NK cells which may support their capacity to lyse leukemic cells.

**Soluble \( \beta_3 \)-integrin Supports NK Cell Cytotoxic Activity**

Above we have reported that \( \beta_3 \)-integrin promotes the secretion of cytotoxic cytokines and caused significant increases in granzyme B transcript levels as well as in FasL protein levels. To investigate the effect of \( \beta_3 \)-integrin in direct capacity of NK to lyse target cells we have performed cytotoxic assays using K562 cells as targets. Significantly higher target cell lysis rates were detected when NK cells exposed to a combination of IL-2 and \( \beta_3 \)-integrin (48.8% ± 7.5%, p < 0.01) in comparison to IL-2 alone (39.1% ± 2.6%). Also, NK cell stimulation with \( \beta_3 \)-integrin alone resulted in a significant enhancement of target cell lysis (36.5% ± 2.5%, p < 0.01) in comparison to non-stimulated NK cells (24.1% ± 2.8%) or stimulated with a control protein (25.6 ± 2.6%) (Figure 6). These data confirm that \( \beta_3 \)-integrin increases the capacity of NK cells to lyse their targets.

**Soluble \( \beta_3 \)-integrin Specifically Increases NK Cell Cytotoxicity against AML Blasts**

To confirm that the effect of soluble \( \beta_3 \)-integrin also enhances NK cell cytotoxic activity against primary leukaemia cells, we have performed NK cell cytotoxic assays using primary AML blasts as targets. In addition, an antibody against \( \beta_3 \)-integrin was used to determine the specificity of the \( \beta_3 \)-integrin effect. NK cells stimulated with \( \beta_3 \)-integrin alone showed a significant increased in AML blast lysis rates (15.3% ± 2.6%, p < 0.01) in comparison to non-stimulated NK cells (6.4% ± 1.6%) or when an antibody against \( \beta_3 \)-integrin was added to the culture (7.9% ± 2.7%). Furthermore, significant increases in AML blast cell lyses (18.4% ± 3.2%, p < 0.01) were observed when NK cells exposed to \( \beta_3 \)-integrin in combination with IL-2 in comparison to stimulation with IL-2 alone (11.8% ± 2.8%). Also this effect was abrogated by the addition of an anti- \( \beta_3 \)-integrin to the cultures (12.2% ± 2.6%, p < 0.03) (Figure 7). These data demonstrate that \( \beta_3 \)-integrin-stimulated NK cells have a superior capacity to lyse primary AML blasts.

**Discussion**

Usually \( \beta_3 \)-integrin is ectopically expressed as a membrane \( \beta_3 \)-unit associated with either \( \alpha_5 \) or \( \alpha_6 \) chains to form \( \alpha_5 \beta_3 \) or \( \alpha_6 \beta_3 \) respectively. A number of alternatively spliced sequences for integrins subunits have been described [27]. Recently, studies have shown that these membrane-bound proteins play a crucial role in angiogenesis, platelet aggregation, and cancer metastasis [7]. In particular, \( \beta_3 \)-integrin has recently been identified in human prostate carcinomas, breast carcinomas, and melanoma cells [6]. In this study, a novel alternative \( \beta_3 \)-integrin transcript was detected in 35% of AML patients with an active form of the disease. Significantly higher \( \beta_3 \)-integrin levels were observed in AML patients prior chemotherapy compared with the \( \beta_3 \)-integrin levels observed after chemotherapy or in healthy individuals. The \( \beta_3 \)-integrin identified in this study resulted from the retention of 92 bp of intron 8, which is different from those previously described [6,17]. Splicing of intron 8 did not cause a shift in the open reading frame, but it led to a premature TAG stop codon at 24 bp downstream from the end of exon 8. Unfortunately, we had no chance to check the molecular weight of the \( \beta_3 \)-integrin due to the limited plasma volume of the patients’ samples.

Unlike cytotoxic T lymphocytes (CTLs), NK cells do not require antigen-specific recognition to lyse their targets [28]. Upon recognition of activating ligands on AML cells, NK cells contribute to lyse leukemic blasts through the secretion of proinflammatory cytokines such as IFN-γ and TNF-α, perforin or granzymes [16,29,30]. Granzyme B plays a major role in NK-mediated cytotoxicity by inducing the apoptosis of their targets [31]. In order to evade the immune response, AML cells secrete soluble factors such as TGF-β and IL-2R [32] that can inhibit both NK cell proliferation and cytotoxicity. Others immunosuppressive factors showed to impair the NK cell proliferation but not the cytolytic function [33]. Therefore, it is important to evaluate the effect of proteins specifically detected in leukemia patients in NK cell function to determine their value as prognosis marker or therapeutic targets. Interestingly, we observed that \( \beta_3 \)-integrin is capable of binding NK cells. However, further studies are required to determine which receptors may be involved in the interaction of \( \beta_3 \)-integrin and NK cells. Nevertheless, our data demonstrated a synergistic effect between \( \beta_3 \)-integrin and IL-2 plus IL-15 in the induction of NK cell proliferation. Previous studies showed that the use of mature alloreactive NK cells has led to a shift in the paradigm of AML therapy [34]. Aiming at increasing the clinical advantage of allo-reactive NK cells, research is now focusing on the expansion of NK cells in vivo and ex vivo [35]. Moreover, the feasibility of ex vivo expanding of donor-derived NK cells populations after activation with soluble factors (e.g. IL-2) is currently being optimized and phase I clinical trials are ongoing [36,37]. Therefore, it might be of clinical relevance to investigate the effect of \( \beta_3 \)-integrin in the expansion and functional properties of alloreactive NK cells. \( \beta_3 \)-integrin did not show the capacity to alter the natural cytotoxicity receptors (NCRs) or lectin-like receptor expression levels on NK cells (data not shown). Interestingly, \( \beta_3 \)-integrin alone or in combination with IL-2 showed to significantly induce the upregulation of granzyme B and FasL (CD95L) levels. These results indicated that \( \beta_3 \)-integrin may support the capacity of NK cells to induce apoptosis of their target cells. Granzyme B is critical in triggering apoptotic AML blasts released during granule exocytosis by NK cells [38]. FasL is intracellularly expressed in resting NK cells and it is translocated into the cell surface upon activation. FasL significantly contributes to the suppression of tumour growth in vivo [39].
NK cells may also induce the apoptosis of AML blasts and contribute to amplify the anti-tumour immune response through the release of proinflammatory cytokines such as IFN-γ and TNF-α [40,41]. In cytokine secretion profiling analyses, β3-integrin promoted the secretion of IFN-γ and TNF-α by NK cells. To investigate the effect of β3-integrin on the capacity of NK to lyse leukemic cells, we performed cytotoxic assays using K562 and primary AML blasts cells as targets. When NK cells were exposed to β3-integrin in presence or absence of IL-2 for 48 hours, their cytotoxic activity against K562 cells and AML blasts was strongly increased. This finding suggests that β3-integrin supports NK cell cytotoxic activity against leukemic target cells. In antibody-mediated blocking experiments, we have shown that the effect of β3-integrin in NK cell cytotoxicity is specific. Antibody-mediated β3-integrin blocking showed to abrogate the enhanced capacity of NK cells to lysis primary AML blasts.

Conclusions

Altogether, the results of this study suggest that β3-integrin is a strong activator of NK-cell cytotoxicity against tumour cells. To our knowledge, this is the first study that demonstrates the presence of a circulating alternative spliced β3-integrin at significantly increased levels in AML patients in the active state of the disease. Further studies will be required to evaluate the potential of using β3-integrin as a prognosis factor or biomarker for AML. Furthermore, β3-integrin may pave the way for the development of novel anti-leukemia therapies by supporting NK cells cytotoxicity against leukemic cells.

Supporting Information

Figure S1 Truncated alternative spliced β3-integrin sequence. The sequence demonstrated that 1–1131 bp was identical to the wild type β3-integrin (GeneBank accession number: NM_000212) and that 1132–1234 bp was derived from intron 8 of β3-integrin gene (underlined). The termination codon is highlighted in bold characters. B. Predicted amino acid composition of the wild type (wt) and truncated (tr) β3 integrin protein. The protein sequence of the alternative spliced truncated β3-integrin was inferred from the cDNA sequence. The first 373 amino acid sequence of the tr β3-integrin is identical to the wt β3-integrin. The amino acids 376–302 of the tr β3-integrin were derived from intron 8 sequence (highlighted in bold letters). The transmembrane region of the wt β3-integrin is underlined. C. Electropherogram shows sequence of intron 8. The first 10 bp belong to exon 8 and then followed by 24 bp of intron 8 (underlined), which ends up with the premature stop codon (TAG).

Table S1 Patient characteristics at diagnosis, among a total of 23 patients.

| Age | Gender | Disease | Therapy | Response |
|-----|--------|---------|---------|----------|
| 10  | M      | AML     | DA      | CR       |
| 20  | F      | ALL     | HA      | PR       |

Acknowledgments

The authors are grateful to Dr. Stefanie Buchholz and Dr. Christiane Gras for helpful discussion.

Author Contributions

Conceived and designed the experiments: YS RB CF. Performed the experiments: YS SV LG AB. Analyzed the data: YS SV BEV AB CF. Contributed reagents/materials/analysis tools: LG AB. Wrote the paper: YS CF.

References

1. Takada Y, Ye X, Simon S (2007) The integrins. Genome Biol 8: 215.
2. Hynes RO (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110: 673-687.
3. Tarone G, Hirsch E, Brancaccio M, De Acetis M, Barberis L, et al. (2000) Integrin function and regulation in development. Int J Dev Biol 44: 725–731.
4. Blencowe BJ (2006) Alternative splicing: new insights from global analyses. Cell 125: 37–47.
5. Brakebush C, Bouvard D, Stanchi F, Sakai T, Fasler R (2002) Integrins in invasive growth. J Clin Invest 109: 999–1006.
6. Jin R, Trikha M, Cai Y, Grignon D, Houn KV (2007) A naturally occurring truncated beta3 integrin in tumor cells: native anti-integrin involved in tumor cell motility. Cancer Biol Ther 6: 1559–1568.
7. Lonsdorf AS, Kramer BF, Fahrleitner M, Schonberger T, Gnerlich S, et al. (2008) A new assay for evaluating anti-leukemia effects of novel agents: a feasibility study in a preclinical in vivo model. J Biomed Biotechnol 2008: 4.
8. Estey E, Dohner H (2006) Acute myeloid leukemia. Lancet 368: 1984–1997.
9. Smits EL, Lee C, Hardwick N, Brooks S, Van Tendeloo VF, et al. (2011) Clinical evaluation of cellular immunotherapy in acute myeloid leukemia. Clin Cancer Res 17: 3757–3769.
10. Ruggeri L, Mancusi A, Burchelli E, Aversa F, Martelli MF, et al. (2007) Natural killer cell alloreactivity in allogeneic hematopoietic transplantation. Curr Opin Oncol 19: 142–147.
11. Verheyden S, Demanet C (2008) NK cell receptors and their ligands in leukemia. Leukemia 22: 249–257.
12. Szczepanski MJ, Szajnik M, Welsh A, Foon KA, Whiteside TL, et al. (2010) Identification and characterization of novel alphaIIbbeta3 (GPIIb/IIIa) ligands in melanoma: a connection to hematogenous metastasis. J Biol Chem 287: 2168–2178.
14. Geller MA, Knorr DA, Hermanson DA, Pribyl L, Bendzick L, et al. (2013) Development of a single-antigen magnetic bead assay (SAMBA) for the sensitive detection of HPA-1a alloantibodies using tag-engineered recombinant soluble beta3 integrin. J Immunol Methods 391: 72–80.
15. Whiteway A, Corbett T, Anderson R, Macdonald I, Premice HG (2003) Expression of costimulatory molecules on acute myeloid leukaemia blasts may effect duration of first remission. Br J Haematol 120: 442–451.
16. Barrett AJ, Le Blanc K (2010) Immunotherapy prospects for acute myeloid leukemia. Clin Exp Immunol 161: 223–232.
17. Djafari I, Chen YP, Cremimont C, Marleaf J, Cierutal AM, et al. (1994) A new alternative transcript encodes a 60 kDa truncated form of integrin beta 3. Biochem J 300 (Pt 1): 69–74.
18. Allen DL, Abrahamsson S, Murphy MF, Roberts DJ (2012) Human platelet antigen 1a epitopes are dependent on the cation-regulated conformation of integrin alphaIIbbeta3 (GPIIb/IIIa). J Immunol Methods 375: 166–175.
19. Skayk A, Battenmann A, Hiller O, Meyer O, Figueredo C, et al. (2013) Development of a single-antigen magnetic bead assay (SAMBA) for the sensitive detection of HPA-1a alloantibodies using tag-engineered recombinant soluble beta3 integrin. J Immunol Methods 391: 72–80.
20. James Y, Figueredo C, Blaichy R (2010) Silencing the expression of platelet endothelial cell adhesion molecule-1 prevents allogeneic T-cell cytotoxicity. Transfusion 50: 1988–2000.
21. Geller MA, Knoor DA, Hermanson DA, Pribyl L, Bendzick L, et al. (2013) Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model. Cytotherapy 15: 1297–1306.
22. Kim HW, Kim JE, Hwang MH, Jeon YH, Lee SW, et al. (2013) Enhancement of natural killer cell cytotoxicity by sodium/iodide symporter gene-mediated radiosensitization in breast cancer cells. PLoS One 8: e70194.
23. Pieper C, Maerk J, Unterberg M, Schwerdtle T, Galla HJ (2014) Brain capillary pericytes contribute to the immune defense in response to cytokines or LPS in vivo. Brain Res.
24. Pardo J, Balkow S, Anel A, Simon MM (2002) Granzymes are essential for natural killer cell-mediated and perf-facilitated tumor control. Eur J Immunol 32: 2881–2887.
25. Eichel G, Wolpert F, Decrey G, Weller M (2013) APO101, a synthetic hexamer CD95 ligand, induces death of human glioblastoma stem-like cells. Anticancer Res 33: 3563–3571.
26. Siena L, Pace E, Ferraro M, Di Sano C, Melis M, et al. (2014) Gemcitabine sensitizes lung cancer cells to Fas/FasL system-mediated killing. Immunology 141: 242–255.

PLOS ONE | www.plosone.org 8 June 2014 | Volume 9 | Issue 6 | e98936
27. Kon S, Atakilit A, Sheppard D (2011) Short form of alpha9 promotes alpha9beta1 integrin-dependent cell adhesion by modulating the function of the full-length alpha9 subunit. Exp Cell Res 317: 1774–1784.
28. Smyth MJ, Cretney E, Kelly JM, Westwood JA, Street SE, et al. (2005) Activation of NK cell cytotoxicity. Mol Immunol 42: 501–510.
29. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S (2008) Functions of natural killer cells. Nat Immunol 9: 503–510.
30. Russell JH, Ley TJ (2002) Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 20: 323–370.
31. Leong JW, Fehniger TA (2011) Human NK cells: SET to kill. Blood 117: 2297–2298.
32. Lion E, Willemen Y, Berneman ZN, Van Tendeloo VF, Smits EL (2012) Natural killer cell immune escape in acute myeloid leukemia. Leukemia 26: 2019–2026.
33. Orleans-Lindsay JK, Barber LD, Prentice HG, Lowdell MW (2001) Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function–implications for the adoptive immunotherapy of leukaemia. Clin Exp Immunol 126: 403–411.
34. Soiffer RJ (2008) Donor lymphocyte infusions for acute myeloid leukaemia. Best Pract Res Clin Haematol 21: 435–466.
35. Ruggeri L, Aversa F, Martelli MF, Vlardi A (2006) Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self. Immunol Rev 214: 202–218.
36. Cho D, Campana D (2009) Expansion and activation of natural killer cells for cancer immunotherapy. Korean J Lab Med 29: 89–96.
37. Koehl U, Sorrensen J, Ecker R, Zimmermann S, Gruttner HP, et al. (2004) IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells Mol Dis 33: 261–286.
38. Guilloton F, Jean C, de Thonel A, Laurent G, Quillet-Mary A (2007) Granzyme B induction signalling pathway in acute myeloid leukemia cell lines stimulated by tumor necrosis factor alpha and Fas ligand. Cell Signal 19: 1132–1140.
39. Wang Z, Gu J, Nie W, Xu J, Huang G, et al. (2013) Quantitative assessment of the association between three polymorphisms in FAS and FASL gene and breast cancer risk. Tumour Biol. 40. Wang R, Jaw JJ, Stutzman NC, Zou Z, Sun PD (2012) Natural killer cell–produced IFN-gamma and TNF-alpha induce target cell cytolysis through up-regulation of ICAM-1. J Leukoc Biol 91: 299–309.
41. Xu G, Zhang Y, Zhang L, Ren G, Shi Y (2008) Bone marrow stromal cells induce apoptosis of lymphoma cells in the presence of IFN-gamma and TNF by producing nitric oxide. Biochem Biophys Res Commun 357: 666–670.